Nexia Biotechnologies Inc.'s Shareholders Approve Sale Of All Assets Associated With Protexia(R)
10/19/2005 5:12:57 PM
MONTREAL, March 8 /CNW Telbec/ - Nexia Biotechnologies Inc. (TSX: NXB)
today announced that its shareholders have approved the sale of substantially
all its operations and assets related to Protexia(R) (recombinant human
butyrylcholinesterase) to a wholly-owned subsidiary of PharmAthene, Inc.
("PharmAthene"), a privately held biotechnology company focused on the
development of biodefense therapeutics, based in Annapolis, Maryland. The
shareholders' vote took place yesterday at Nexia's Annual and Special Meeting
of Shareholders held at the Hilton Montreal Airport Hotel, Montreal, QC and
the transaction is scheduled to close later this week.